Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib

Among the noteworthy recent stories in the management and prevention of atherosclerotic cardiovascular disease (CVD) is the saga of the development of pharmacological inhibitors of cholesteryl ester transfer protein (CETP). Inhibiting CETP significantly raises plasma concentrations of high-density l...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldberg, Alyse S, Hegele, Robert A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460676/
https://www.ncbi.nlm.nih.gov/pubmed/23055695
http://dx.doi.org/10.2147/DDDT.S34976

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460676/
https://www.ncbi.nlm.nih.gov/pubmed/23055695
http://dx.doi.org/10.2147/DDDT.S34976

Ejemplares similares